{
    "symbol": "THTX",
    "quarter": 1,
    "year": 2022,
    "date": "2022-04-13 14:55:04",
    "content": " Earlier this week, the company presented the three posters at the recently attended AACR annual meeting, including new in vivo TH1902 preclinical data demonstrating tumor growth inhibition of human cancer stem-like cells CD133+ in both triple negative breast and ovarian cancers. For the first quarter of fiscal 2022, net sales of EGRIFTA SV reached $11.7 million compared to $8.7 million in Q1 of last year, representing an increase of 35%, due to the combined effect of a higher number of units sold, and a higher net selling price."
}